Anti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines

Prognosis of childhood acute lymphoblastic leukemia (ALL) has been dramatically improved. However, prognosis of the cases refractory to primary therapy is still poor. Recent phase 2 study on the efficacy of combination chemotherapy with bortezomib (BTZ), a proteasome inhibitor, for refractory childh...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Kazuya, Inukai, Takeshi, Imamura, Toshihiko, Yano, Mio, Tomoyasu, Chihiro, Lucas, David M., Nemoto, Atsushi, Sato, Hiroki, Huang, Meixian, Abe, Masako, Kagami, Keiko, Shinohara, Tamao, Watanabe, Atsushi, Somazu, Shinpei, Oshiro, Hiroko, Akahane, Koshi, Goi, Kumiko, Kikuchi, Jiro, Furukawa, Yusuke, Goto, Hiroaki, Minegishi, Masayoshi, Iwamoto, Shotaro, Sugita, Kanji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728482/
https://www.ncbi.nlm.nih.gov/pubmed/29236701
http://dx.doi.org/10.1371/journal.pone.0188680

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728482/
https://www.ncbi.nlm.nih.gov/pubmed/29236701
http://dx.doi.org/10.1371/journal.pone.0188680

Ejemplares similares